Bio-Techne, a global life sciences company, has partnered with Oxford-based mass photometry specialist Refeyn to launch a new workflow for antibody analysis. The collaboration integrates Bio-Techne's protein reagents with Refeyn's OneMP mass photometry platform, enabling researchers to rapidly assess antibody size, purity, and target binding without the need for labelling or complex sample preparation.
The new workflow is designed to streamline early-stage drug development, particularly in the biopharmaceutical sector where monoclonal antibodies are a key therapeutic class. By providing real-time, high-resolution data on antibody interactions, the partnership aims to reduce the time and cost associated with lead candidate selection.
Dr. Amanda Roberts, a senior analyst at UK life sciences consultancy BioInsight, noted: 'This collaboration addresses a critical bottleneck in antibody development. The ability to measure binding affinity and aggregation in minutes, rather than hours, could significantly accelerate preclinical pipelines.'
For UK investors, the announcement underscores the growing commercialisation of advanced analytical tools in the life sciences sector. Bio-Techne, listed on the Nasdaq, has a significant presence in the UK through its distribution network, while Refeyn continues to expand its footprint in Oxford's innovation cluster. The partnership may also signal increased demand for contract research services that leverage these technologies.
The broader implications for UK pension holders and retail investors lie in the potential for improved drug development efficiency to bolster returns for pharmaceutical and biotech stocks held within diversified portfolios. However, as with all emerging technologies, adoption rates and regulatory clearance will determine long-term financial impact.
Source: Bio-Techne press release